The American College of Rheumatology (ACR) has updated its health policy statements for 2018, and biosimilars featured heavily in the organization’s concerns for the year ahead.
The American College of Rheumatology (ACR) has updated its health policy statements for 2018, and biosimilars featured heavily in the organization’s concerns for the year ahead.
ACR underscored its support of biosimilars, which it recently voiced in detail in the group’s white paper on biosimilars, saying that the organization is “committed to advocating for a smooth transition to an era of less expensive biologics that provide safe, effective treatments that are accessible to more people.” ACR says that it remains opposed to forced switching of patients’ therapy, and also opposes legislation or regulation that permits a pharmacist to substitute a biologic or biosimilar for another (unless the pharmacist is acting in accordance with a collaborative practice agreement with the prescriber). In jurisdictions where such legislation exists, providers must retain the right to demand that a prescription be dispensed as written, says ACR.
The organization also calls for biologic medicine administration to be reimbursed at the complex rate under Medicare Part B, saying that, in recent years, a growing number of contractors have stopped reimbursing at this rate without consulting with physicians, as required by law. “Reduced reimbursement and coverage for medically necessary care and treatment will force doctors to reduce services they offer. Therefore, without proper coverage of these treatments, access to therapy is threatened.”
ACR says that specialty tiers for biologic medicines that require high patient cost sharing also pose a barrier to care, and that federal, state, and local legislation should restrict such tiering by commercial insurance carriers. Other legislative tools to reduce out-of-pocket costs, such as caps on total annual out-of-pocket spending, should be explored.
The organization also expresses concerns about patient assistance programs for high-cost drugs like biologics and biosimilars; while having the benefit of providing access to critical treatments for patients who otherwise would be unable to afford their medicines, patient assistance programs insulate patients from drug costs and may distort demand for lower-cost therapies, such as biosimilars. “As such, these programs may be best paired with other measures to reduce drug list prices, and are suboptimal compared to basic cost coverage strategies,” says the ACR.
However, as long as Medicare does not cover the cost of crucial treatments, the ACR says that it will support increased access to these programs for Medicare Part D beneficiaries, and will support legislation that would allow Part B and Part D beneficiaries to receive financial copay assistance as part of these programs. It also opposes insurance restrictions preventing the application of funds from assistance programs to patients’ deductibles and out-of-pocket minimums.
Finally, in order to address the high cost of medicines, ACR supports legislation that would allow Medicare to negotiate directly with pharmaceutical companies to achieve more affordable pricing of drugs, and says that there must be increased transparency in how drug companies, pharmacy benefit managers, and payers determine the costs of medicines.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.